Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended Jun... (AP measures to their most closelyapplica...)

Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008

Date:8/6/2008

AP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Below is a reconciliation of adjusted net earnings available to common shareholders and adjusted diluted EPS to GAAP net (loss) earnings available to common shareholders and diluted GAAP EPS:

Three months Three months

ended ended

($'s in millions except per

share amounts) June 30, 2008 June 30, 2007

GAAP net (loss) earnings available

to common shareholders & diluted

GAAP EPS $(8.4) $(0.03) $79.7 $0.32

Purchase accounting related

amortization (1) 112.1 18.8

Specialty Segment profitability (19.7) -

Loss on foreign currency contract - 57.5

Bystolic revenue (9.8) -

Integration and other non-recurring

expenses (2) 35.8 -

Tax effect of the above items (3) (62.4) (27.1)

Adjusted net earnings available to

common shareholders and adjusted

diluted EPS $47.6 $0.16 $128.9 $0.52

(1) The three months ended June 30, 2008 include amortization expense related to purchased intangible assets as well as amortization of the inventory step-up related to Merck Generics. The three months ended June 30, 2007 include amortization expense related to purchased intangible assets as well as amortization of the inventory step-up related to Matrix.

(2) The three months ended June 30, 2008, include non-recurring expenses principally relate
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.

Post Your Comments:

Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended Jun...(AP measures to their most closelyapplica...),Health